Table I.
Number (and percent) of antimicrobial resistant methicillin-resistant Staphylococcus pseudintermedius (MRSP) isolates overall and by dru cluster, following Clinical Laboratory Standards Institute (CLSI) guidelines. Multidrug resistance (MDR) in each cluster is also reported
| Antimicrobial | Overall (n = 94) | 9a (n = 18) | 10h (n = 27) | 11a (n = 45) | No cluster (n = 4) |
|---|---|---|---|---|---|
| Amikacin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0%) |
| Chloramphenicol | 23 (24.5%) | 3 (16.7%) | 0 (0%) | 19 (42.2%) | 1 (25%) |
| Clindamycin | 54 (57.5%) | 16 (88.9%) | 7 (25.9%) | 29 (64.4%) | 2 (50%) |
| Doxycycline | 14 (14.9%) | 1 (5.6%) | 7 (25.9%) | 4 (8.9%) | 2 (50%) |
| Erythromycin | 63 (67.0%) | 17 (94.4%) | 11 (40.7%) | 32 (71.1%) | 3 (75%) |
| Enrofloxacin | 46 (48.9%) | 16 (88.9%) | 0 (0%) | 29 (64.4%) | 1 (25%) |
| Fusidic acid | 2 (2.1%) | 1 (5.6%) | 1 (3.7%) | 0 (0%) | 0 (0%) |
| Gentamicin | 34 (36.2%) | 10 (55.6%) | 2 (7.4%) | 20 (44.4%) | 2 (50%) |
| SXT | 70 (74.5%) | 18 (100%) | 23 (85.2%) | 27 (60.0%) | 2 (50%) |
| MDR | 66 (70.2%) | 17 (94.4%) | 15 (55.6%) | 31 (68.9%) | 3 (75%) |
SXT — trimethoprim-sulfamethoxazole.